Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15747
Abstract: AIMS This study aimed to assess safety, tolerability, pharmacokinetic and pharmacodynamic effects of ensovibep, a DARPin antiviral being evaluated as a COVID-19 treatment, in healthy volunteers in a first-in-human ascending single-dose study. METHODS Subjects were… read more here.
Keywords: single dose; ascending single; healthy volunteers; human ascending ... See more keywords